Targeting Immunity in End-Stage Renal Disease

Slides:

Advertisements

Similar presentations

Fig. 4-1, p Fig. 4-2, p. 109 Fig. 4-3, p. 110.

Advertisements

P.464. Table 13-1, p.465 Fig. 13-1, p.466 Fig. 13-2, p.467.

Fig. 11-1, p p. 360 Fig. 11-2, p. 361 Fig. 11-3, p. 361.

Table 6-1, p Fig. 6-1, p. 162 p. 163 Fig. 6-2, p. 164.

Renal Replacement Therapy for Prevention of Contrast- induced Acute Kidney Injury: A Meta-analysis of Randomized Controlled Trials Source Song K, Jiang.

© 2016 S. Karger AG, Basel. All rights reserved Metabolomics of Chronic Kidney Disease Progression: A Case-Control Analysis in the Chronic Renal Insufficiency.

The LIVES Sub-analysis

A.M. Thompson, T.G. Pickering Kidney International

Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury Yan Xie, Benjamin Bowe, Tingting Li, Hong Xian,

Am J Nephrol 2013;38: DOI: / Fig. 1. Study selection process.

Renal Parenchymal Hypoxia, Hypoxia Response and the Progression of Chronic Kidney Disease Am J Nephrol 2008;28:998– DOI: / © 2008.

Pulmonary Hypertension Is Associated with Mortality and Cardiovascular Events in Chronic Kidney Disease Patients Am J Nephrol 2017;45: DOI: /

Locatelli et al. Am J Nephrol 2017;45: (DOI: / )

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

Acute Kidney Injury and In-Hospital Mortality after Coronary Artery Bypass Graft versus Percutaneous Coronary Intervention: A Nationwide Study Shen et.

Figure 4 Interplay between acute kidney injury (AKI),

Figure 5 Inter-relationships between sleep apnoea, CKD and brain injury Figure 5 | Inter-relationships between sleep apnoea, CKD and brain injury. In chronic.

Kuwabara et al. Am J Nephrol 2017;45: (DOI: / )

Nat. Rev. Nephrol. doi: /nrneph

Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease Martin et al. Am J Nephrol 2017;45: (DOI:

Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury Yan Xie, Benjamin Bowe, Tingting Li, Hong Xian,

Bhandari et al. Am J Nephrol 2017;45: (DOI: / )

Lilia Cervantes, Monica Grafals, Rudolph A. Rodriguez

Mitchell H. Rosner, W. Kline Bolton Kidney International

Bushinsky et al. Am J Nephrol 2016;44: (DOI: / )

Volume 83, Issue 3, Pages (March 2013)

Impact of Cognitive Function Change on Mortality in Renal Transplant and End-Stage Renal Disease Patients Sharma et al. Am J Nephrol 2016;44: (DOI: / )

Chronic Kidney Disease Classification in Systolic Blood Pressure Intervention Trial: Comparison Using Modification of Diet in Renal Disease and CKD-Epidemiology.

Management of hypertension in patients with chronic kidney disease

Susan P.Y. Wong, MD, Ann M. O'Hare, MD, MA

Figure 1 The burden of chronic kidney disease (CKD)

Figure 4 The gut–kidney axis, inflammation and cardiovascular disease in CKD Figure 4 | The gut–kidney axis, inflammation and cardiovascular disease in.

Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease Torres et al. Am J.

Hammoud et al. Am J Nephrol 2016;44: (DOI: / )

Trial analysis results comparing ACE inhibitors/ARBs with other antihypertensive drugs on renal disease progression End point Relative risk (95% CI) p.

A Pathological Scoring System to Predict Renal Outcome in Diabetic Nephropathy Am J Nephrol 2015;41: DOI: / Fig. 1. Renal survival.

Psychosocial Factors and 30-Day Hospital Readmission among Individuals Receiving Maintenance Dialysis: A Prospective Study Flythe et al. Am J Nephrol 2017;45:

Andrew Narva American Journal of Kidney Diseases

I. Introduction American Journal of Kidney Diseases

Your Kidneys May Outlive You

Pregnancy Outcomes in Patients with Glomerular Disease Attending a Single Academic Center in North Carolina O'Shaughnessy et al. Am J Nephrol 2017;45:

End-stage renal disease in living kidney donors

Adjusted relative risk for developing end-stage renal disease (ESRD) associated with blood-pressure level BP level (mm Hg) Adjusted relative risk 95%

A New Era of Renal Denervation Trials for Patients With Hypertension?

Volume 70, Issue 11, Pages (December 2006)

Nat. Rev. Nephrol. doi: /nrneph

Langsford et al. Am J Nephrol 2017;45: (DOI: / )

Baseline Characteristics by Tertiles of Homocysteine

Volume 86, Issue 1, Pages (July 2014)

A Timely Evaluation of the Psychometric Properties of the KDQOL-36

American Journal of Kidney Diseases

Nat. Rev. Neurol. doi: /nrneurol

Nowak et al. Am J Nephrol 2016;44: (DOI: / )

A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease S. Susan Hedayati, Venkata Yalamanchili,

Prehypertension: is it relevant for nephrologists?

Aaron M. Drucker, MD, Paula J. Harvey, PhD

Cardiovascular risk in chronic kidney disease

Recurrent Vascular Access Dysfunction as a Novel Marker of Cardiovascular Outcome and Mortality in Hemodialysis Patients Kim et al. Am J Nephrol 2016;44:71-80.

Is complement a target for therapy in renal disease?

James F. Winchester, MD, Thomas H. Hostetter, MD, Timothy W. Meyer, MD

Volume 75, Issue 7, Pages (April 2009)

Genetic Features of Chinese Patients with Gitelman Syndrome:

Potential links between the immune dysfunction in uremia, inflammation, infection, and increased risk of atherosclerosis and cardiovascular disease. Potential.

Mortality caused by cardiovascular disease (A) and sepsis (B) of patients with end-stage renal disease (ESRD) treated by dialysis compared with the general.

Darshi et al. Am J Nephrol 2016;44: (DOI: / )

Causal diagrams that represent three possible relationships between smoking, ESRD, and albumin-to-creatinine ratio (ACR) in the Study of Heart and Renal.

Possible outcomes of therapeutic treatments using the spiral model.

Fistula and Survival Outcomes after Fistula Creation among Predialysis Chronic Kidney Disease Stage 5 Patients Miyamoto et al. Am J Nephrol 2017;45:

Avasare et al. Am J Nephrol 2017;45:99-106 (DOI: / )

Proposed future revascularisation strategy in patients with ESRD based on our current results and previous guideline recommendations. Proposed future revascularisation.

Presentation transcript:

Targeting Immunity in End-Stage Renal Disease Baragetti et al. Am J Nephrol 2017;45:310-319 (DOI:10.1159/000458768) Table 1. Evidence of a relationship between inflammation markers and cardiovascular risk

Targeting Immunity in End-Stage Renal Disease Baragetti et al. Am J Nephrol 2017;45:310-319 (DOI:10.1159/000458768) Table 2. Experimental therapies aimed at reducing inflammation in preclinical models of CKD and ESRD

Targeting Immunity in End-Stage Renal Disease Baragetti et al. Am J Nephrol 2017;45:310-319 (DOI:10.1159/000458768) Fig. 1. Schematic attempt to show pathways that may be targeted or are currently being targeted in ESRD.